Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07195682 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
A Phase 1 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 125
- Enrollment target
- 9
- Study locations
NCT07195682: Recruiting Phase 1 study of Renal Cell Carcinoma, sponsored by Bristol-Myers Squibb.
NCT07195682 is a Phase 1 study of Renal Cell Carcinoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 125 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (48% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07195682, a Phase 1 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 125 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
Conditions Studied
Interventions
- DRUG BMS-986506
Study Locations (9)
Massachusetts
- Local Institution - 0006 - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Local Institution - 0002 - Philadelphia
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- START San Antonio - San Antonio
Alberta
- Arthur J.E. Child Comprehensive Cancer Centre - Calgary
Val-de-Marne
- Local Institution - 0008 - Villejuif
Andalusia
- Local Institution - 0015 - Córdoba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2031-04-03 |
| Phase | Phase 1 |
What NCT07195682 shows while recruiting
NCT07195682 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which BMS-986506 is the first listed.
NCT07195682 lists 9 locations in 9 states (Massachusetts, New York, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT07195682 about?
NCT07195682 is a clinical study titled "A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)". This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
What is the current status of trial NCT07195682?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 125 participants. The study started on 2026-01-15. Estimated completion is 2031-04-03.
What conditions does trial NCT07195682 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT07195682?
The interventions under investigation include: BMS-986506 (DRUG).
Who is sponsoring clinical trial NCT07195682?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07195682 being conducted?
This trial has 9 study locations across Massachusetts, New York, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07195682's enrollment target sits among peer trials
125 45th of 121 higher than 77 of 121 other Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI